Pancreatic Cancer

The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

The key to the future of pancreatic cancer treatment is immunotherapy, according to Gregory L. Beatty, MD, PhD.

Bolstering the effectiveness of T cells and the further implementation of AI can both yield positive results in the future of pancreatic cancer treatment.

Shubham Pant, MD, MBBS, highlights how pan-RAS inhibitors, RAS-directed vaccines, and biomarker testing can improve outcomes in pancreatic cancer.

Immunohistochemistry presents a solution to the obstacles that the different identified cellular neighborhoods in pancreatic tumors create.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

The incorporation of palliative care specific to mental health services and therapy remains underutilized in the care of patients with pancreatic cancer.

A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.

Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.

It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.

Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.

The 18-month overall survival rate with the mitazalimab combination in OPTIMIZE-1 exceeds a historical rate achieved with FOLFIRINOX alone.

The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

Results from the CANFOUR trial of combining nadunolimab with chemotherapy appear to prolong overall survival among those with advanced or metastatic PDAC.

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

Experts in gastrointestinal cancer focus on frontline therapy options for patients with pancreatic cancer.

Data from the interim analysis of the ACCENT trial showed promising signs of efficacy with narmafotinib combination therapy in advanced pancreatic cancer.

Research shows that patients with pancreatic ductal adenocarcinoma are frequently understaged prior to surgery.

Adding metastasis-free directed radiation to chemotherapy more than tripled progression-free survival vs chemotherapy alone in the EXTEND trial.

FDA acceptance is based on phase 3 CABINET trial results, with cabozantinib showing a PFS improvement in patients with pancreatic neuroendocrine tumors.

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.

Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.